Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings

Imagem de Miniatura
Arquivos
art_VELASQUES_Less_Intensive_Regimens_May_Still_Be_Suitable_for_2022.PDF (547.13 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI LTD
Autores
Citação
JOURNAL OF ONCOLOGY, v.2022, article ID 2099456, 9p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Primary mediastinal B-cell lymphoma (PMBCL) is an uncommon disease, consisting of 2-4% of non-Hodgkin lymphomas. Radiotherapy-free DA-EPOCH-R and R-CHOP plus radiotherapy (RT) have been the upfront standard regimens worldwide. However, performing DA-EPOCH-R in resource-constrained settings can be burdensome, especially in low/middle-income countries, where data on PMBCL are still largely unknown. We retrospectively analyzed 93 patients with PMBCL diagnosed between 2008 and 2018 with the intention of comparing the characteristics of the patients and the results obtained with each protocol and to verify if the use of less intensive chemotherapy is still possible to be used. The median age was 28 years, 59.1% were female, 42.3% were in advanced stages, and 92.1% were with bulky disease. DA-EPOCH-R (41.9%), R-CHOP (35.5%), and R-CHOEP (22.6%) were the regimens used, and no difference was observed in the characteristics of the patients. After four cycles of chemotherapy, complete response (CR), partial response (PR), and progressive disease (PD) rates were 40%, 55.7%, and 4.5%, respectively. At the end of treatment, metabolic CR and PD rates were 56.8% and 11.1%. RT was performed in 42.1% of DA-EPOCH-R, 75% of R-CHOP, and 83% of R-CHOEP, and switched PR to CR in 73.7%. Estimated 5-year PFS and OS were 77.2% and 77.4%, respectively. Only LDH levels remained independently associated with PFS, and type of treatment was not associated with OS, PFS, or relapse rate. Therefore, we conclude that in a resource-constrained setting, R-CHOP or R-CHOEP could be still safely adopted in upfront treatment for PMBCL.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/48252
Referências
  1. Avigdor A, 2014, ANN HEMATOL, V93, P1297, DOI 10.1007/s00277-014-2043-y
  2. Bhatt VR, 2015, CANCER TREAT REV, V41, P476, DOI 10.1016/j.ctrv.2015.04.006
  3. Cavanaugh JE, 1997, STAT PROBABIL LETT, V33, P201, DOI 10.1016/S0167-7152(96)00128-9
  4. Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244
  5. Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800
  6. Cwynarski K, 2019, BRIT J HAEMATOL, V185, P402, DOI 10.1111/bjh.15731
  7. Dunleavy K, 2013, NEW ENGL J MED, V368, P1408, DOI 10.1056/NEJMoa1214561
  8. Eule C, 2020, ACTA ONCOL, V59, P786, DOI 10.1080/0284186X.2020.1744718
  9. Gaulard P., 2017, WHO CLASSIFICATION T, P314
  10. Giulino-Roth L, 2018, BLOOD, V132, P782, DOI 10.1182/blood-2018-04-791566
  11. Giulino-Roth L, 2017, BRIT J HAEMATOL, V179, P739, DOI 10.1111/bjh.14951
  12. Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
  13. Higgins JP, 1999, AM J CLIN PATHOL, V112, P241
  14. International Extranodal Lymphoma Study Group (IELSG), IELSG37
  15. Jackson MW, 2016, AM J HEMATOL, V91, P476, DOI 10.1002/ajh.24325
  16. Lekovic D, 2010, THROMB RES, V126, P477, DOI 10.1016/j.thromres.2010.08.017
  17. Li Chan EH, 2019, CANCER MED-US, V8, P4626, DOI 10.1002/cam4.2347
  18. Malenda A, 2020, EUR J HAEMATOL, V104, P59, DOI 10.1111/ejh.13337
  19. Melani C, 2018, HAEMATOLOGICA, V103, P1337, DOI 10.3324/haematol.2018.192492
  20. Moskowitz CH, 2010, J CLIN ONCOL, V28, P1896, DOI 10.1200/JCO.2009.26.5942
  21. Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7
  22. Pohlen M, 2011, AM J HEMATOL, V86, pE61, DOI 10.1002/ajh.22165
  23. Rieger M, 2011, ANN ONCOL, V22, P664, DOI 10.1093/annonc/mdq418
  24. Savage KJ, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.303.303
  25. Savage KJ, 2006, ANN ONCOL, V17, P123, DOI 10.1093/annonc/mdj030
  26. Scrucca L, 2007, BONE MARROW TRANSPL, V40, P381, DOI 10.1038/sj.bmt.1705727
  27. Shah NN, 2018, BRIT J HAEMATOL, V180, P534, DOI 10.1111/bjh.15051
  28. Soumerai JD, 2014, LEUKEMIA LYMPHOMA, V55, P538, DOI 10.3109/10428194.2013.810738
  29. Swerdlow S., 2008, WHO CLASSIFICATION T
  30. Vassilakopoulos TP, 2021, ONCOLOGIST, V26, P597, DOI 10.1002/onco.13789
  31. Vassilakopoulos TP, 2012, ONCOLOGIST, V17, P239, DOI 10.1634/theoncologist.2011-0275
  32. Wang Bing-Jie, 2014, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V22, P1596, DOI 10.7534/j.issn.1009-2137.2014.06.018
  33. Whittington MD, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0035
  34. Yang XQ, 2021, J MED ECON, V24, P469, DOI 10.1080/13696998.2021.1908001
  35. Zhou H, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0312-7
  36. Zinzani PL, 2009, CLIN LYMPHOMA MYELOM, V9, P381, DOI 10.3816/CLM.2009.n.074

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03